WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: Pharma stocks decline; Aurobindo Pharma down over 4% — Warptech Lab News

Storia in 8 fonti

Pharma stocks decline; Aurobindo Pharma down over 4%

Pharma stocks fall as Aurobindo Pharma drops over 4% following Trump's tariff announcement on imported generic medicines.

Raccontata da

hindustantimes.com

thehindubusinessline.com

economictimes.indiatimes.com

newsbytesapp.com

timesofindia.indiatimes.com

asia.nikkei.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo1 mese fa

Pharma stocks decline; Aurobindo Pharma down over 4%

Pharma stocks fall as Aurobindo Pharma drops over 4% following Trump's tariff announcement on imported generic medicines.

Timeline cronologica

mercoledì 22 luglio 2026·hindustantimes.com
US to impose steep tariffs on generic medicine imports from Aug 2028
US to impose steep tariffs on generic medicine imports from Aug 2028
mercoledì 22 luglio 2026·thehindubusinessline.com
Why these 8 stocks including Pharma majors will remain in focus on today following Trump’s tariff announcement
Maruti Suzuki’s price hike, Anant Raj demerger, Aurobindo Pharma getting nod for bio similar, Anupam Rasayn open offer to Bliss GVS shareholders

timesofindia.indiatimes.com

1 mese fa

Pharma stocks bleed after Trump announces up to 200% tariff on generic drugs; Aurobindo, Sun Pharma & Cipla…

Pharmaceutical stocks came under pressure on Wednesday after US President Donald Trump unveiled a phased tariff plan for imported generic medicines, raising concerns over the long-term outlook for one of the industry's…

Leggi questa versione → originale

economictimes.indiatimes.com1 mese fa

Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investors

Indian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact companies with substantial US revenue exposure. Analysts suggest investors…

Leggi questa versione → originale

theprint.in1 mese fa

Stocks fall, pharma firms fret. Indian drug manufacturers sweat over Trump's 100% levy on generics

Trump proposed 100% tariffs on generics; Indian pharma (50% of US supply, $10.5B exports) cannot practically relocate in two years. The move disrupts globally integrated supply chains and risks escalating US healthcare costs, signaling reshoring pressure for manufacturing sectors.

Leggi questa versione → originale

hindustantimes.com1 mese fa

0% for two years, 100% for one, 200 after: US' latest tariff move over generic medicines

In 2025, India exported USD 9.7 billion worth of pharmaceuticals to the US, accounting for 38 per cent of its total global pharma exports of USD 25.8 billion. | India News

Leggi questa versione → originale

channelnewsasia.com1 mese fa

India's pharma sector braces for impact of proposed Trump tariffs on generic drugs

Analysts warn the levies could disrupt global drug supply chains, push up medicine prices for Americans and force Indian drugmakers to rethink their manufacturing strategies.

Leggi questa versione → originale

mercoledì 22 luglio 2026·

hindustantimes.com

0% for two years, 100% for one, 200 after: US' latest tariff move over generic medicines

In 2025, India exported USD 9.7 billion worth of pharmaceuticals to the US, accounting for 38 per cent of its total global pharma exports of USD 25.8 billion. | India News

mercoledì 22 luglio 2026·

economictimes.indiatimes.com

Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028

Indian pharma stocks are likely to remain in focus after US President Donald Trump announced a phased tariff plan for generic medicines, offering a two-year tariff exemption…

mercoledì 22 luglio 2026·

newsbytesapp.com

Trump threatens tariff on generic medicines: Should India be worried?

US President Trump announced a two-year tariff exemption for imported generic medicines, warning of steep 200% duties if production doesn't shift to the US afterward.

mercoledì 22 luglio 2026·

hindustantimes.com

0, 100, 200: How Trump's latest generic medicines tariffs could affect India

Indian drugmakers export around $9-10 billion worth of generic medicines to the American market every year. | India News

mercoledì 22 luglio 2026·

theprint.in

0% now, 100% in 2 years, 200% by 2029—US plan for generic pharma tariffs & what it means for India

US to impose no tariff on generic pharmaceutical goods initially, before hiking to 200%. Announcement set to impact India as US accounts for third of pharma exports from nation.

mercoledì 22 luglio 2026·

timesofindia.indiatimes.com

Pharma stocks bleed after Trump announces up to 200% tariff on generic drugs; Aurobindo, Sun Pharma & Cipla slide over 3%

Pharmaceutical stocks came under pressure on Wednesday after US President Donald Trump unveiled a phased tariff plan for imported generic medicines, raising concerns over the…

mercoledì 22 luglio 2026·

economictimes.indiatimes.com

Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufacturing and supply chain strategies. After…

mercoledì 22 luglio 2026·

thehindubusinessline.com

Pharma stocks decline; Aurobindo Pharma down over 4%

Pharma stocks fall as Aurobindo Pharma drops over 4% following Trump's tariff announcement on imported generic medicines.

mercoledì 22 luglio 2026·

economictimes.indiatimes.com

Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?

The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one hundred percent, eventually reaching…

mercoledì 22 luglio 2026·

economictimes.indiatimes.com

Trump’s 100% generic drug duty threatens US low-cost supply

President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028, rising to 200% a year later. The move…

mercoledì 22 luglio 2026·

economictimes.indiatimes.com

200% Trump tariff shock? India’s cheap pills may still beat US rivals

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage…

mercoledì 22 luglio 2026·

economictimes.indiatimes.com

Indian pharma firms may yet survive Trump's 200% tariff bombshell

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited.…

mercoledì 22 luglio 2026·

economictimes.indiatimes.com

Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors

Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be…

mercoledì 22 luglio 2026·

timesofindia.indiatimes.com

Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive

In a blow to India’s pharmaceutical industry, the Donald Trump administration has announced up to 200% tariffs on generic drugs that will be applicable in the coming years.

mercoledì 22 luglio 2026·

thehindubusinessline.com

US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline

US tariff threats lead to a 1.4% drop in Nifty Pharma, with Lupin and Auropharma experiencing significant declines.

mercoledì 22 luglio 2026·

asia.nikkei.com

Trump's generic drugs tariff threatens Indian pharma's top market

100% levy from 2028 could accelerate push into higher value medicines

mercoledì 22 luglio 2026·

zerohedge.com

UBS Warns Trump's 100% Generic Drug Tariff Puts Indian Pharma "On Notice"; Goldman Flags Reshoring Winners

"For our generics coverage, we view the group as relatively well-positioned given: AMRX (significant US infrastructure), TEVA..."

mercoledì 22 luglio 2026·

timesofindia.indiatimes.com

US tariffs could raise drug prices, squeeze Indian generics

NEW DELHI: India's $30-billion pharma industry is staring at a fresh challenge after US President Donald Trump announced that generic medicines imported into the US would face…

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com